IBDEI0GC ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7576,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,7577,0)
 ;;=611.1^^35^473^16
 ;;^UTILITY(U,$J,358.3,7577,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7577,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,7577,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,7577,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,7578,0)
 ;;=704.1^^35^473^17
 ;;^UTILITY(U,$J,358.3,7578,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7578,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,7578,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,7578,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,7579,0)
 ;;=251.2^^35^473^30
 ;;^UTILITY(U,$J,358.3,7579,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7579,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,7579,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,7579,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,7580,0)
 ;;=253.2^^35^473^34
 ;;^UTILITY(U,$J,358.3,7580,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7580,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,7580,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,7580,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,7581,0)
 ;;=733.00^^35^473^43
 ;;^UTILITY(U,$J,358.3,7581,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7581,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,7581,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,7581,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,7582,0)
 ;;=278.00^^35^473^40
 ;;^UTILITY(U,$J,358.3,7582,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7582,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,7582,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,7582,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,7583,0)
 ;;=278.01^^35^473^39
 ;;^UTILITY(U,$J,358.3,7583,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7583,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,7583,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,7583,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,7584,0)
 ;;=250.80^^35^473^10
 ;;^UTILITY(U,$J,358.3,7584,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7584,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,7584,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,7584,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,7585,0)
 ;;=250.00^^35^473^5
 ;;^UTILITY(U,$J,358.3,7585,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7585,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,7585,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,7585,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,7586,0)
 ;;=250.40^^35^473^6
 ;;^UTILITY(U,$J,358.3,7586,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7586,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,7586,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,7586,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,7587,0)
 ;;=250.50^^35^473^9
 ;;^UTILITY(U,$J,358.3,7587,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7587,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,7587,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,7587,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,7588,0)
 ;;=250.60^^35^473^7
 ;;^UTILITY(U,$J,358.3,7588,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7588,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,7588,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
 ;;^UTILITY(U,$J,358.3,7588,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,7589,0)
 ;;=250.70^^35^473^8
 ;;^UTILITY(U,$J,358.3,7589,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7589,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,7589,1,5,0)
 ;;=5^DM Type II Dm with Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,7589,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,7590,0)
 ;;=250.01^^35^473^4
 ;;^UTILITY(U,$J,358.3,7590,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7590,1,4,0)
 ;;=4^250.01
 ;;
 ;;$END ROU IBDEI0GC
